Dar3A螯合剂的开发及FAP靶向PET探针的构建:概念验证与首次人体评价
本研究合成新型大环螯合剂Dar3A,并与DOTA比较68Ga和177Lu的标记效率及热力学稳定性。Dar3A偶联FAP抑制剂-04后制备[68Ga]Ga-SMIC-3101,在细胞、U87MG荷瘤小鼠及3名健康志愿者和1例食管癌患者中完成概念验证与首次人体评价,显示安全且能清晰显示原发和转移灶。
要点
- Dar3A对68Ga和177Lu的标记效率优于DOTA,[68Ga]Ga-SMIC-3101摩尔活度为28.7 MBq/nmol。
- U87MG荷瘤小鼠中[68Ga]Ga-SMIC-3101 2和4小时肿瘤摄取分别为12.73±1.68和10.64±2.88 %ID/g,显著高于DOTA基[68Ga]Ga-FAPI-04的0.66±0.22和0.51±0.10 %ID/g。
- 首次人体研究显示[68Ga]Ga-SMIC-3101安全,主要经肝胆系统生理性排泄,可清晰显示食管癌原发和转移病灶。
核心结论
- Dar3A是一种有前景的双功能螯合剂,可用于放射性标记和生物偶联,支持诊疗一体化放射性药物的开发。
研究设计与样本
- 合成新型大环螯合剂Dar3A并修饰侧臂用于生物偶联,与DOTA进行滴定实验评估热力学稳定性及68Ga和177Lu标记效率比较。
- 将Dar3A与源自成纤维细胞激活蛋白抑制剂-04的FAP靶向部分偶联,用68Ga标记制备[68Ga]Ga-SMIC-3101,在细胞实验、动物模型及人体受试者(3名健康志愿者和1例食管癌患者)中评价。
主要发现
- Dar3A对68Ga和177Lu的放射性标记效率优于DOTA,[68Ga]Ga-SMIC-3101的摩尔活度为28.7 MBq/nmol。
- U87MG荷瘤小鼠中[68Ga]Ga-SMIC-3101 2小时肿瘤摄取为12.73±1.68 %ID/g、4小时为10.64±2.88 %ID/g,均显著高于DOTA基[68Ga]Ga-FAPI-04的2小时0.66±0.22 %ID/g和4小时0.51±0.10 %ID/g。
- 首次人体研究显示[68Ga]Ga-SMIC-3101安全,生理性排泄主要经肝胆系统,可清晰显示食管癌原发和转移病灶。
关键数值与推荐
- Dar3A对68Ga和177Lu的标记效率优于DOTA。
- [68Ga]Ga-SMIC-3101摩尔活度为28.7 MBq/nmol。
- U87MG荷瘤小鼠中[68Ga]Ga-SMIC-3101 2小时肿瘤摄取12.73±1.68 %ID/g、4小时10.64±2.88 %ID/g,显著超过DOTA基[68Ga]Ga-FAPI-04的2小时0.66±0.22 %ID/g和4小时0.51±0.10 %ID/g。
- 首次人体研究纳入3名健康志愿者和1例食管癌患者,[68Ga]Ga-SMIC-3101安全,主要经肝胆系统生理性排泄,可清晰显示食管癌原发和转移病灶。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Developing novel radiopharmaceuticals for cancer theranostics has recently attracted extensive interest. Bifunctional chelators are key components of many radiometal-based radiopharmaceuticals. For the established 68Ga/177Lu theranostic pair, the commonly used chelator DOTA suffers from some issues, such as the requirement for heating during radiolabeling and slow chelation kinetics. The limitations highlight the need to develop new bifunctional chelators. Methods: The novel macrocyclic chelator 2-[11,27-bis(carboxymethyl)-34,36-dihydroxy-7,23-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.15,9113,17121,25]hexatriaconta-1(33),5(36),6,8,13,15,17(35),21(34),22,24,29,31-dodecaen-3-yl]acetic acid (Dar3A) was synthesized and modified with a pendant arm for bioconjugation. A comprehensive comparison with DOTA was performed, including titration experiments to assess thermodynamic stability and radiolabeling studies to evaluate the efficiency of 68Ga and 177Lu labeling. For a proof of concept, Dar3A was conjugated with a fibroblast activation protein-targeted moiety derived from fibroblast activation protein inhibitor-04 and radiolabeled with 68Ga to prepare [68Ga]Ga-SMIC-3101. The resulting 68Ga-labeled radiotracer was further evaluated in cellular assays, animal models, and human subjects (3 healthy volunteers and 1 patient with esophageal cancer). Results: Dar3A exhibited superior radiolabeling efficiency with 68Ga and 177Lu compared with DOTA, and [68Ga]Ga-SMIC-3101 was obtained with a molar activity of 28.7 MBq/nmol. In U87MG tumor-bearing mice, [68Ga]Ga-SMIC-3101 exhibited enhanced tumor uptake (12.73 ± 1.68 and 10.64 ± 2.88 %ID/g at 2 and 4 h, respectively), significantly exceeding that of DOTA-based [68Ga]Ga-FAPI-04 (0.66 ± 0.22 and 0.51 ± 0.10 %ID/g, respectively). Moreover, the first-in-human study demonstrated that [68Ga]Ga-SMIC-3101 was safe, with physiologic excretion occurring primarily via the hepatobiliary system, and clearly visualized primary and metastatic esophageal cancer lesions. Conclusion: Dar3A is a promising bifunctional chelator for radiolabeling and bioconjugation, supporting theranostic radiopharmaceutical development.
引用
- Li R, Cao R, Zhang G, et al. Development of Dar3A Chelator and Construction of FAP-Targeted PET Probe as Proof of Concept and for First-in-Human Evaluation. J Nucl Med. 2026. PMID: 41956560. doi:10.2967/jnumed.125.271421
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。